Amyloid beta1-40 quantification in CSF: comparison between chromatographic and immunochemical methods

A H Simonsen; S F Hansson; U Ruetschi; J McGuire; V N Podust; H A Davies; P Mehta; G Waldemar; H Zetterberg; N Andreasen; A Wallin; K Blennow

doi:10.1159/000100020

Amyloid beta1-40 quantification in CSF: comparison between chromatographic and immunochemical methods

A H Simonsen, S F Hansson, U Ruetschi, J McGuire, V N Podust, H A Davies, P Mehta, G Waldemar, H Zetterberg, N Andreasen, A Wallin, K Blennow

Afdeling for Hjerne- og Nervesygdomme

Abstrakt

BACKGROUND/AIMS: Amyloid beta (Abeta) is the principal component of senile plaques, one of the hallmarks of Alzheimer's disease (AD). Evidence is accumulating that soluble aggregates (oligomers) of Abeta are important in the pathogenesis of AD.

METHODS: We compared three different methods for quantification of the 40 amino acid form of Abeta (Abeta40) in CSF, two based on antibodies [ELISA and surface-enhanced laser desorption/ionization-time of flight (SELDI-TOF) with antibody-coated arrays] and one based on direct binding of proteins to a protein array [SELDI-TOF and immobilized metal affinity [copper] (IMAC30)].

RESULTS: CSF Abeta40 concentration was only found to be significantly elevated in AD (127% of control levels; p=0.0095) using SELDI-TOF with IMAC30 arrays.

CONCLUSIONS: These data suggest that the measured Abeta level in CSF may differ depending on whether antibody-based methods are used or not, possibly caused by epitope masking due to Abeta oligomerization or to binding of Abeta to carrier proteins.

Originalsprog	Engelsk
Tidsskrift	Dementia and Geriatric Cognitive Disorders
Vol/bind	23
Udgave nummer	4
Sider (fra-til)	246-50
Antal sider	5
ISSN	1420-8008
DOI	https://doi.org/10.1159/000100020
Status	Udgivet - 2007

Adgang til dokumentet

10.1159/000100020

Citationsformater

Simonsen, A. H., Hansson, S. F., Ruetschi, U., McGuire, J., Podust, V. N., Davies, H. A., Mehta, P., Waldemar, G., Zetterberg, H., Andreasen, N., Wallin, A., & Blennow, K. (2007). Amyloid beta1-40 quantification in CSF: comparison between chromatographic and immunochemical methods. Dementia and Geriatric Cognitive Disorders, 23(4), 246-50. https://doi.org/10.1159/000100020

@article{d76e23c9bab8454b888dcca7d3c3f989,

title = "Amyloid beta1-40 quantification in CSF: comparison between chromatographic and immunochemical methods",

abstract = "BACKGROUND/AIMS: Amyloid beta (Abeta) is the principal component of senile plaques, one of the hallmarks of Alzheimer's disease (AD). Evidence is accumulating that soluble aggregates (oligomers) of Abeta are important in the pathogenesis of AD.METHODS: We compared three different methods for quantification of the 40 amino acid form of Abeta (Abeta40) in CSF, two based on antibodies [ELISA and surface-enhanced laser desorption/ionization-time of flight (SELDI-TOF) with antibody-coated arrays] and one based on direct binding of proteins to a protein array [SELDI-TOF and immobilized metal affinity [copper] (IMAC30)].RESULTS: CSF Abeta40 concentration was only found to be significantly elevated in AD (127% of control levels; p=0.0095) using SELDI-TOF with IMAC30 arrays.CONCLUSIONS: These data suggest that the measured Abeta level in CSF may differ depending on whether antibody-based methods are used or not, possibly caused by epitope masking due to Abeta oligomerization or to binding of Abeta to carrier proteins.",

keywords = "Aged, Aged, 80 and over, Alzheimer Disease/cerebrospinal fluid, Amyloid beta-Peptides/analysis, Biomarkers/analysis, Cerebrospinal Fluid/chemistry, Enzyme-Linked Immunosorbent Assay/methods, Female, Humans, Immunochemistry/methods, Male, Peptide Fragments/analysis, Reference Values, Reproducibility of Results, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization/methods",

author = "Simonsen, {A H} and Hansson, {S F} and U Ruetschi and J McGuire and Podust, {V N} and Davies, {H A} and P Mehta and G Waldemar and H Zetterberg and N Andreasen and A Wallin and K Blennow",

year = "2007",

doi = "10.1159/000100020",

language = "English",

volume = "23",

pages = "246--50",

journal = "Dementia and Geriatric Cognitive Disorders",

issn = "1420-8008",

publisher = "S./Karger AG",

number = "4",

}

TY - JOUR

T1 - Amyloid beta1-40 quantification in CSF

T2 - comparison between chromatographic and immunochemical methods

AU - Simonsen, A H

AU - Hansson, S F

AU - Ruetschi, U

AU - McGuire, J

AU - Podust, V N

AU - Davies, H A

AU - Mehta, P

AU - Waldemar, G

AU - Zetterberg, H

AU - Andreasen, N

AU - Wallin, A

AU - Blennow, K

PY - 2007

Y1 - 2007

N2 - BACKGROUND/AIMS: Amyloid beta (Abeta) is the principal component of senile plaques, one of the hallmarks of Alzheimer's disease (AD). Evidence is accumulating that soluble aggregates (oligomers) of Abeta are important in the pathogenesis of AD.METHODS: We compared three different methods for quantification of the 40 amino acid form of Abeta (Abeta40) in CSF, two based on antibodies [ELISA and surface-enhanced laser desorption/ionization-time of flight (SELDI-TOF) with antibody-coated arrays] and one based on direct binding of proteins to a protein array [SELDI-TOF and immobilized metal affinity [copper] (IMAC30)].RESULTS: CSF Abeta40 concentration was only found to be significantly elevated in AD (127% of control levels; p=0.0095) using SELDI-TOF with IMAC30 arrays.CONCLUSIONS: These data suggest that the measured Abeta level in CSF may differ depending on whether antibody-based methods are used or not, possibly caused by epitope masking due to Abeta oligomerization or to binding of Abeta to carrier proteins.

AB - BACKGROUND/AIMS: Amyloid beta (Abeta) is the principal component of senile plaques, one of the hallmarks of Alzheimer's disease (AD). Evidence is accumulating that soluble aggregates (oligomers) of Abeta are important in the pathogenesis of AD.METHODS: We compared three different methods for quantification of the 40 amino acid form of Abeta (Abeta40) in CSF, two based on antibodies [ELISA and surface-enhanced laser desorption/ionization-time of flight (SELDI-TOF) with antibody-coated arrays] and one based on direct binding of proteins to a protein array [SELDI-TOF and immobilized metal affinity [copper] (IMAC30)].RESULTS: CSF Abeta40 concentration was only found to be significantly elevated in AD (127% of control levels; p=0.0095) using SELDI-TOF with IMAC30 arrays.CONCLUSIONS: These data suggest that the measured Abeta level in CSF may differ depending on whether antibody-based methods are used or not, possibly caused by epitope masking due to Abeta oligomerization or to binding of Abeta to carrier proteins.

KW - Aged

KW - Aged, 80 and over

KW - Alzheimer Disease/cerebrospinal fluid

KW - Amyloid beta-Peptides/analysis

KW - Biomarkers/analysis

KW - Cerebrospinal Fluid/chemistry

KW - Enzyme-Linked Immunosorbent Assay/methods

KW - Female

KW - Humans

KW - Immunochemistry/methods

KW - Male

KW - Peptide Fragments/analysis

KW - Reference Values

KW - Reproducibility of Results

KW - Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization/methods

U2 - 10.1159/000100020

DO - 10.1159/000100020

M3 - Journal article

C2 - 17310122

VL - 23

SP - 246

EP - 250

JO - Dementia and Geriatric Cognitive Disorders

JF - Dementia and Geriatric Cognitive Disorders

SN - 1420-8008

IS - 4

ER -

Amyloid beta1-40 quantification in CSF: comparison between chromatographic and immunochemical methods

Abstrakt

Adgang til dokumentet

Fingeraftryk

Citationsformater